Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAL0140
- Development stage
- Phase 2
- Lead developer
- Shenzhen Salubris Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAL0140 is a small molecule, investigational aldosterone synthase inhibitor developed primarily for the treatment of hypertension and chronic kidney diseases. Its mechanism is the antagonism of aldosterone biosynthesis, targeting the aldosterone pathway to reduce aldosterone levels. Clinical trials are ongoing to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects, including effects on plasma and urinary aldosterone and potential cardiac implications. It is being developed by Shenzhen Salubris Pharmaceuticals.
- Brand names
- SAL0140SAL-0140SAL 0140
- Other names
- SAL0140SAL-0140SAL 0140
02
Targets
CYP11B2 (Cytochrome P450 11B2)
Beyond the preview
Go deeper on SAL0140.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAL0140.